Physician profile
Stephen R Ruyle
NPI 1558300483
$9,083.15
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $902 · 2021: $1,682 · 2022: $2,141 · 2023: $2,403 · 2024: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.22 |
| Education | $115.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,160.21 | 2019-2024 | Erleada, Akeega |
| Astellas Pharma US INC | $1,091.26 | 2019-2024 | Xtandi |
| Abbvie INC. | $821.80 | 2019-2024 | Botox, Lupron Depot, Avycaz |
| Sumitomo Pharma America, INC. | $517.00 | 2023-2024 | Orgovyx, Gemtesa |
| Pfizer INC. | $493.41 | 2019-2024 | |
| Myovant Sciences INC. | $490.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $445.88 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $397.21 | 2019-2023 | Xiaflex |
| Allergan, INC. | $282.25 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $277.27 | 2022-2024 | Pylarify |
| Amgen INC. | $272.90 | 2019-2023 | Xgeva |
| Merck Sharp & Dohme LLC | $201.38 | 2022-2023 | Welireg, Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $193.93 | 2021-2023 | Lynparza |
| Blue Earth Diagnostics | $191.45 | 2019-2022 | |
| Neotract INC. | $163.16 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ruyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.